An announcement from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC has completed an off-market purchase of 44,155,844 ordinary shares from Pfizer Inc. for approximately £170 million, subsequently canceling these shares. This transaction affects the total voting rights and capital structure, with the number of ordinary shares with voting rights now standing at 9,035,489,870. This adjustment is significant for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company offers a diverse range of products across five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. Haleon’s portfolio includes well-known brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are recognized for their trusted science and innovation.
YTD Price Performance: 4.40%
Average Trading Volume: 25,029,369
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £35.41B
See more data about HLN stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com